Atezolizumab in non-squamous non-small cell lung cancer

Sentinel Node Mapping in Non-small Cell Lung Cancer Using an Intraoperative Radiotracer Technique

 Objective(s): Lymph node metastases are the most significant prognostic factor in localized non-small cell lung cancer (NSCLC). Identification of the first nodal drainage site (sentinel node) may improve detection of metastatic nodes. Extended surgeries, such as lobectomy or pneumonectomy with lymph node dissection, are among the therapeutic options of higher acceptab...

Clinicopathological Features of Patients with Non-small-cell Lung Cancer in West of Iran

Background: Lung cancer is the most common cause of cancer death worldwide with an annual mortality rate of more than 1.3 million worldwide. We aimed to analyze the clinicopathological features of patients with non-small-cell lung cancer (NSCLC) in west of Iran. Methods: 64 patients with NSCLC who referred to our clinic were analyzed. Sex, age, histopathology, location of the tumor, treatment,...

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab

The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies. Lung cancer has been in the forefront of checkpoint inhibition for the past 2 years and has paved the path for other subspecialties. While PD-1 inhibitors nivolumab and pembrolizumab have been approved for non-small cell lung cancer (NSCLC), this review focuses on atezoliz...

Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

H Endon et al (JCO 2004;22:811-9). Selected 8 genes out of 44 detected as prognostic markers of adenocarcinoma (Garber et al PNAS USA 98;13784-9, 2001 and Bhattachorjee et al PNAS USA 98;13790-5, 2001): PTK 7 (HR 0.5), CIT (HR 0.6), SCNNIA (HR 1.7), PGES (HR 2.2), EST-LB4D (HR 1.9), ERO 1l (HR 0.2), EST-AA434256 (HR 0.4) and ZWINT (HR 2.3). Low risk group had a 85% 5 y OS and high risk 40% 5 y OS.